Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $1.5B | $404M | $234M | $349M | 21.4% | 0.5% | -25.2% |
| 2024 | $1.5B | $515M | $312M | $465M | 28.7% | 18.3% | -4.4% |
| 2023 | $1.3B | $491M | $327M | $259M | 40.0% | 38.6% | 1063.9% |
| 2022 | $935M | $82M | $28M | $263M | 6.3% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 1,541.61 |
| Operating Revenue | 1,541.61 |
| Cost Of Revenue | 599.66 |
| Gross Profit | 941.95 |
| Operating Expense | 626.39 |
| Research And Development | 177.31 |
| Selling General And Administration | 453.81 |
| Total Expenses | 1,226.05 |
| Operating Income | 315.56 |
| Total Operating Income As Reported | 310.83 |
| EBITDA | 403.64 |
| Normalized EBITDA | 409 |
| EBIT | 333.54 |
| Interest Income | 23.39 |
| Interest Expense | 19.75 |
| Net Interest Income | 3.64 |
| Other Non Operating Income Expenses | -0.05 |
| Other Income Expense | -5.41 |
| Interest Income Non Operating | 23.39 |
| Interest Expense Non Operating | 19.75 |
| Net Non Operating Interest Income Expense | 3.64 |
| Pretax Income | 313.79 |
| Tax Provision | 80.23 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | -1.37 |
| Net Income Continuous Operations | 233.56 |
| Net Income From Continuing And Discontinued Operation | 233.56 |
| Net Income From Continuing Operation Net Minority Interest | 233.56 |
| Net Income | 233.56 |
| Net Income Common Stockholders | 233.56 |
| Net Income Including Noncontrolling Interests | 233.56 |
| Normalized Income | 237.54 |
| Diluted NI Availto Com Stockholders | 233.56 |
| Basic Average Shares | 67.49 |
| Diluted Average Shares | 68.44 |
| Reconciled Depreciation | 70.10 |
| Reconciled Cost Of Revenue | 599.66 |
| Total Unusual Items | -5.36 |
| Total Unusual Items Excluding Goodwill | -5.36 |
| Special Income Charges | 4.27 |
| Other Special Charges | 0.73 |
| Gain On Sale Of Security | -9.62 |
| General And Administrative Expense | 275.12 |
| Other Gand A | 275.12 |
| Gain On Sale Of Ppe | 5 |
| Other Operating Expenses | -4.73 |
| Selling And Marketing Expense | 178.69 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Lantheus Holdings, Inc.this co. | LNTH | $6.7B | 28.66 | 6.14 | 21.4% | 17.23 |
| HealthEquity, Inc. | HQY | $7.2B | 33.42 | 3.41 | 10.2% | 16.10 |
| Oscar Health, Inc. | OSCR | $7.1B | -16.06 | 7.28 | -45.3% | - |
| Vaxcyte, Inc. | PCVX | $7.0B | -9.18 | 2.62 | -28.5% | -7.77 |
| Apogee Therapeutics, Inc. | APGE | $6.9B |
| - |
| - |
| - |
| - |
| - |
| - |
| -26.79 |
| 7.58 |
| -28.3% |
| -23.68 |
| Spyre Therapeutics, Inc. | SYRE | $6.8B | - | 9.53 | -21.7% | - |
| Arcellx, Inc. | ACLX | $6.7B | -29.41 | 16.73 | -56.9% | -30.17 |
| Immunovant, Inc. | IMVT | $6.7B | -13.27 | 7.87 | -59.3% | -10.90 |
| Hims & Hers Health, Inc. | HIMS | $6.5B | 50.51 | 11.99 | 23.7% | 46.06 |
| Peer Median | - | -13.27 | 7.72 | -28.4% | -9.34 | |